Efficacy Prediction of Autologous Platelet-Rich Plasma (PRP) against Sub-clinical Bubaline Mastitis
Efficacy Prediction of Autologous Platelet-Rich Plasma (PRP) against Sub-clinical Bubaline Mastitis
Qamar Ullah1,2, Muti-ur-Rehman Khan1*, Raheela Akhtar1 and Aftab Ahmad Anjum3
Fig. 1.
Box and whiskers plot for cellular concentrations (platelets, WBCs, and RBCs) in whole blood and PRP.
Fig. 2.
Receiver Operating Characteristic (ROC) curve predictive of the therapeutic efficacy of PRP against Sub-clinical bubaline mastitis. The area under the curve (0.73) indicates the autologous PRP is an acceptable therapeutic.
Fig. 3.
Comparison of the mean rank difference of autologous PRP, combination of PRP + antibiotic and antibiotic against sub-clinical bubaline mastitis. The rank means having different superscripts are significantly different at (P < 0.05).
